In a bid to expand presence in the cell therapy space,
) recently announced that it has entered into a global licensing
and research collaboration agreement with privately-held
biopharmaceutical company, Regenerex.
As per the agreement, Novartis will gain access to Regenerex's
proprietary stem cell based therapy platform Facilitating Cell
Therapy (FCRx) which is being evaluated for kidney
The stem cell based therapy aims to induce stable
immunological tolerance in kidney transplantation. Additionally,
FCRx can also be evaluated for the treatment of serious genetic
deficiencies such as inherited metabolic storage disorders and
The addition of FCRx will expand Novartis' existing cell
therapy portfolio which already has two cell therapy platforms -
HSC835 and CTL019. Both are being evaluated for hematological
While HSC835 is being evaluated in patients with high-risk
hematological malignancies in a phase I study, CTL019 is being
developed in a phase II study for the treatment of acute
lymphoblastic leukemia and chronic lymphocytic leukemia.
We note that apart from stem cell therapy based treatments,
Novartis also markets a drug - Glivec, which is approved for the
treatment of ALL and chronic myeloid leukemia.
We remind investors that other companies which are developing
cell based therapies include
) and Israel-based
Pluristem Therapeutics Inc.
While Celgene is carrying out research on stem cells derived
from the human placenta as well as from the umbilical cord for
the treatment of different diseases, Pluristem develops
placenta-based cell therapies using the company's proprietary
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
) looks well placed with a Zacks Rank #2 (Buy).
CELGENE CORP (CELG): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
PLURISTEM THERA (PSTI): Free Stock Analysis
To read this article on Zacks.com click here.